Arctic Bioscience – Board approval of share capital increase related to share option exercise
Reference is made to the stock exchange release published by Arctic Bioscience 27th February 2023 regarding exercise of share options and corresponding issuance of new shares in Arctic Bioscience.
On 7th of March 2023, the Board of Arctic Bioscience, on the basis of a board authorization granted by the Company’s General Meeting on 5th May 2022, resolved to increase the share capital from NOK 2 437 571,90 to NOK 2 442 571,90 by subscription of 50 000 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 9,845 per share, including a share premium of NOK 9,745 per share.
The total amount paid as share premium is NOK 487 250. The total subscription amount is NOK 492 250. Following the registration of this share capital increase in the Norwegian Register of Business Enterprises, the Company’s share capital will be NOK 2 442 571,90 divided into 24 425 719 shares, each having a nominal value of NOK 0,10.
Minutes from Board Meeting is attached hereto.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.
For more information, please contact:
Christer L. Valderhaug
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.